University of Colorado grants license to Cirena for RNA-synthesis technology
Life Science Newswire– has secured a license to the Â鶹Ãâ·Ñ°æÏÂÔØ’s patented RNA synthesis technology, giving researchers scalable access to high-purity 100-400nt RNA constructs for next-generation therapeutics. The agreement brings to market an approach developed at Â鶹Ãâ·Ñ°æÏÂÔØBoulder, enabling reliable synthesis of long RNA needed to support rapidly developing applications in CRISPR, functional genomics, and emerging RNA-therapeutic modalities.
Patents and Licensing Opportunities for Â鶹Ãâ·Ñ°æÏÂÔØBioscience Technologies
Biosciences are crucial for advancing medical knowledge and improving patient care. At the University of Colorado, cutting-edge research in these fields is driving significant breakthroughs. The university's advanced facilities and collaborative environment enable researchers to delve into areas such as molecular medicine, regenerative therapies and personalized healthcare. By translating scientific discoveries into innovative treatments and technologies, Â鶹Ãâ·Ñ°æÏÂÔØis at the forefront of improving health outcomes and enhancing the quality of life for people around the world.
CU’s focus on bioscience research discoveries stems from a strong ecosystem of interdisciplinary collaboration that facilitates the transition from laboratory discoveries to market-ready technologies.
The Newsroom
For marketing and communication inquiries or news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at Â鶹Ãâ·Ñ°æÏÂÔØBoulder.
For media inquiries, please visit .